Pfizer/Merck KGaA End Bavencio Ovarian Cancer Phase III Study science science / science 5 years ago 322 Views comments Pfizer (PFE) and Merck KGaA terminate a late-stage study on Bavencio. This is the second ovarian cancer study failure in less than two months. Read more
Comments